Keating, M. J., O’Brien, S., Albitar, M., Lerner, S., Plunkett, W., Giles, F., et al. (2005) Early results of a chemoim- munotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. Journal of Clinical Oncology, 23, 4079-4088. doi:10.1200/JCO.2005.12.051

has been cited by the following article:

• TITLE: A comparison of flow cytometry detection of minimal residual disease and chimerism kinetics in chronic lymphocytic leukemia patients after allogeneic hematopoietic stem cell transplantation

  AUTHORS: Adriana Plesa, Xavier Thomas, Quoc Hung Le, Anne-Sophie Michallet, Valérie Dubois, Charles Dumontet, Mauricette Michallet

  KEYWORDS: Chronic lymphocytic leukemia, allogeneic stem cell transplantation, minimal residual disease, chimerism

  JOURNAL NAME: Journal of Biomedical Science and Engineering, Vol.4 No.3, March 8, 2011

  ABSTRACT: Determination of minimal residual disease (MRD) remains crucial for the follow-up after therapy in chronic lymphocytic leukemia (CLL) patients. Chimerism was assessed by short tandem repeat (STR)-PCR and single nucleotide polymorphisms (SNP)-PCR, and MRD by a multicolor flow cytometric approach in 12 consecutive patients with CLL after they received allogeneic stem cell transplantation (SCT). Overall, 11 patients achieved MRD flow negativity [10 had full donor chimerism (FDC) and one had mixed chimerism (MC)]. Only one patient remained with MRD flow positivity and displayed MC. Fifty-six samples were concomitantly studied by both chimerism and MRD flow. A significant correlation was observed between MRD flow data and chimerism in both PB and BM by using a mixed effect linear regression (p